Bortezomib (PS-341)

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bortezomib (PS-341) Chemical Structure

Bortezomib (PS-341) Chemical Structure
Molecular Weight: 384.24

Validation & Quality Control

Product Use Citation(142)

Customer Product Validation(20)

Quality Control & MSDS

Related Compound Libraries

Proteasome Inhibitors with Unique Features

  • Pan Proteasome Inhibitor

    Ixazomib (MLN2238) β5 site, IC50=3.4 nM; β1 site, IC50=31 nM; β2 site, IC50=3500 nM.

  • FDA-approved Proteasome Inhibitor

    Carfilzomib (PR-171) Approved by FDA for multiple myeloma.

  • Newest Proteasome Inhibitor

    Oprozomib (ONX 0912) Orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM.

  • Classic Proteasome Inhibitor

    ONX-0914 (PR-957) Selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome.

Product Information

  • Compare Proteasome Inhibitors
    Compare Proteasome Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets 20S proteasome [1]
(Cell-free assay)
IC50 0.6 nM(Ki)
In vitro Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
MCF-7MmnQR5l1d3SxeHnjJGF{e2G7MXS1NEDPxE1?NFXEO|A1QCCqMVnEUXNQMoj4T4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=>NWPCT3pEOTB2OUm2OFM>
OVCA 429MYTGeY5kfGmxbjDBd5NigQ>?M2DhOlMxOCCwTR?=M4PJe|Q5KGh?NEL5[2tFVVORM2XJcGRqe3K3cITzJIlvfGGldDDteYx1cWOnbHz1cIFzKHS3bX;yJJNxcGW{b3nkdy=>NGTURmcyODl7OUe2Oi=>
RPMI8226Mmj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4\rSlExOCCwTR?=NEO3RW01QCCqNVvkW5hSTE2VTx?=MnG0TWM2OD1|MDDuUS=>MXuxNVMxPjR6OR?=
Dox40NWG5NlBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXX[2cyODBibl2=NGf0NGo1QCCqMorxSG1UVw>?MmDrTWM2OD12MDDuUS=>MmDSNVE{ODZ2OEm=
MR20MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1LaZlExOCCwTR?=M3n0XFQ5KGh?Mn\2SG1UVw>?NXXYRlJqUUN3ME2yNEBvVQ>?MVWxNVMxPjR6OR?=
LR5NVvPeIh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHFZ|VrOTByIH7NMUW0PEBpMVnEUXNQMlTQTWM2OD1{MDDuUS=>MWSxNVMxPjR6OR?=
U266Ml2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXSxNFAhdk1?Mn\0OFghcA>?M3\1SWROW09?NHi1e21KSzVyPUOgcm0>M{ftc|EyOzB4NEi5
IM-9NHPvN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HCOlExOCCwTR?=M3:yXlQ5KGh?NVjxSmtjTE2VTx?=Ml70TWM2OD14IH7NMnOxNVE{ODZ2OEm=
Hs SultanMkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVLnR2dSOTByIH7NNHLXV4k1QCCqNGPaelFFVVORNVrrNXpSUUN3ME2yNEBvVQ>?MW[xNVMxPjR6OR?=
PAM-LY2M2\0PGZ2dmO2aX;uJGF{e2G7NV7JNW12OTByIH7NNX:zXINPOTJiaB?=M1:1dmROW09?NYPlPWYxUW6qaXLpeJMhVkZvzsrCJIFkfGm4YYTpc44>M4\H[VEyOzVyOUGz
PAM 212NXXnco04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nVeVExOCCwTR?=M{jE[lczKGh?MonJSG1UVw>?MUHJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?NEHmTHcyOTN3MEmxNy=>
PAM-LY2MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mny1NVAxKG6PMnK3O|IhcA>?NGn4d21FVVORM{e4S2lvcGmkaYTzJINmdGxidnnhZoltcXS7M3i0fVEyOzVyOUGz
B4B8NVW4do9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYWxNFAhdk1?NYjybmJDPzJiaB?=Mn\BSG1UVw>?MmDlTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?MWGxNVM2ODlzMx?=
B7E3NXXIdGhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7hV4MyODBibl2=MUK3NkBpNG\LZYhFVVORNIq3T5ZKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?=MnnLNVE{PTB7MUO=
UM-SCC-9NYjmOoJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2m2VVExOCCwTR?=M4nvTlczKGh?M1ywXmROW09?MnGzTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl?NEnifoIyOTN3MEmxNy=>
UM-SCC-11BMmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHJZnQyODBibl2=MlTlO|IhcA>?Ml;nSG1UVw>?MVjJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>?MXexNVM2ODlzMx?=
H460M4TxRmZ2dmO2aX;uJGF{e2G7M1XaXlExKM7:TR?=MXqyOEBpMWPEUXNQMV7JcoR2[2W|IFLjcE0zKHCqb4PwbI9zgWyjdHnvckBidmRiY3zlZZZi\2ViY3;ydoVt[XSnZDD3bZRpKEd{LV2gdIhie2ViYYLy[ZN1NHfHSmMyOjR7MkGxOy=>
U266NFzPSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NISxPGg2ODBibnevcYw>M{i3OFQ5KGh?M{TXU2ROW09?MUHJcohq[mm2czDj[YxtKGe{b4f0bC=>M1TNXFEzPjNzNkG5
ARH77M1rVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXe1NFAhdmdxbXy=NWXKNJQxPDhiaB?=M1XDeWROW09?NGW0T|hKdmirYnn0d{Bk\WyuIHfyc5d1cA>?M1rEUVEzPjNzNkG5
WAD-1M4PDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkniOVAxKG6pL33sMkPFOFghcA>?Mn25SG1UVw>?NEDZS45KdmirYnn0d{Bk\WyuIHfyc5d1cA>?MYixNlY{OTZzOR?=
U266/LR7MlnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HQeFUxOCCwZz;tcC=>M2nEPVQ5KGh?MWfEUXNQM{SzVWlvcGmkaYTzJINmdGxiZ4Lve5RpNF3Ico4yOjZ|MU[xPS=>
U266/dox4NHrEUmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TZdlUxOCCwZz;tcC=>NUDuc5p6PDhiaB?=MVTEUXNQMVfJcohq[mm2czDj[YxtKGe{b4f0bC=>NVXrTZM{OTJ4M{G2NVk>
RPMI8226/LR5M4rSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXO1NFAhdmdxbXy=NWDUUYxVPDhiaB?=MXfEUXNQNHSyN|ZKdmirYnn0d{Bk\WyuIHfyc5d1cA>?NH25fFUyOjZ|MU[xPS=>
H460MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUC1R|lnOTBizszNM1XLOFczKGh?NVTCVHFjTE2VTx?=MoLETWM2OD1zMECgcm0>MkPXNVI3OzF4MkC=
H358Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDOT24yOCEQvF2=NIjYRmI4OiCqMl3RSG1UVw>?MVHJR|UxRTdyIH7NNV62R|lROTJ4M{G2NlA>
H322Ml71S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUT4XYxlOTBizszNMUm3NkBpNH2ycmJFVVORNEC1THJKSzVyPU[yNEBvVQ>?M3XSdFEzPjNzNkKw
H460Mn3vSpVv[3Srb36gRZN{[Xl?MXexNFAhdk1?MmHUNlQhcA>?NFrLRodFVVORNVvYSWZiUW6mdXPld{BIOi2PLYDoZZNmKGG{cnXzeEBidmRidIXieYxqdiCjc4PlcYJtgS2maYPhd5NmdWKueR?=NEK0RlkyOjZ|MU[yNC=>
LNCap-Pro5M{LtWmZ2dmO2aX;uJGF{e2G7M{nsTFEh|ryPMlWyOEBpMXPEUXNQNX3jOlV6W3SjYnnsbZpmeyCyNUO=M1LPTVE1PjF{NUOy
T29M4\Lb2Fxd3C2b4Ppd{BCe3OjeR?=NXnoeHpsPTBibl2=M1H2TVQ5KGhiMWPEUXNQNGSyeFBKdmS3Y3XzJINmdGxiYYDvdJRwe2m|MWmxOlc4QDF5OR?=
T29Kt1NGXGVIRCeG:ydH;zbZMhSXO|YYm=M1\Kd|UxKG6PMXq0PEBpKA>?Mor5SG1UVw>?MlHRTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?NXHzZ5JxOTZ5N{ixO|k>
HCT116NEnpVoRCeG:ydH;zbZMhSXO|YYm=NFzTd3I2OCCwTR?=NUf0UG9TPDhiaDC=MWPEUXNQNVO3e|hnUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=M{LSPVE3Pzd6MUe5
HKe-3M2G1XWFxd3C2b4Ppd{BCe3OjeR?=NUjDV3BFPTBibl2=Ml7pOFghcCB?NGHjdldFVVORMlrwTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?MUSxOlc4QDF5OR?=
NB-1691MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13aTVEh|ryPMW[3NkBpNV;oPItzUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEWlMV:xO|Y5QTZ6NB?=
CHLA-255NVvXfZk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MluwNUDPxE1?MkLqO|IhcA>?MVfJcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36geI8hOiV?NWXVdY5COTd4OEm2PFQ>
SK-N-ASMYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUj0NYZ3OSEQvF2=NYH2VWNOPzJiaB?=M2HreWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW=NHu2bWwyPzZ6OU[4OC=>
NB-1691NF;4[VVHfW6ldHnvckBCe3OjeR?=NWG1WYp1OTBibl2=NUHrRXZFOjRiaB?=NUfWRVdWW2mpbnnmbYNidnSueTDy[YR2[2W|IHPlcIx{KGmwIITo[UBIOC:JMTDwbIF{\Q>?M37ObFE4Pjh7Nki0
CHLA-255MXzGeY5kfGmxbjDBd5NigQ>?MlvXNVAhdk1?MmjRNlQhcA>?NXnKbFF3VW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W=NIjac4gyPzZ6OU[4OC=>
RPMI 8226Mn;kSpVv[3Srb36gRZN{[Xl?M4XobVIxKG6PMl;JPEBpM3S3WnNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6NIrSVGsyQTR|NkC1NC=>
MM.1SMWnGeY5kfGmxbjDBd5NigQ>?NYnXR29yOjBibl2=M1rTXVghcA>?NGjCW41UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>?M1nY[|E6PDN4MEWw
U266NXy0PWxKTnWwY4Tpc44hSXO|YYm=NGXmRWMzOCCwTR?=MXy4JIg>NEjOb45UcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>?MYqxPVQ{PjB3MB?=
OPM1NYixbZF6TnWwY4Tpc44hSXO|YYm=MmjzNlAhdk1?NEPoXXo5KGh?M4n6Z3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6NUnWW|dwOTl2M{[wOVA>
INA6MUXGeY5kfGmxbjDBd5NigQ>?NYrQemtNOjBibl2=NYHycGRUQCCqM{L0[XNq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6NEfhfJkyQTR|NkC1NC=>
OPM2MmLSSpVv[3Srb36gRZN{[Xl?NFnE[|UzOCCwTR?=NIjjRpo5KGh?NYGxV2xQW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl?NGDR[5QyQTR|NkC1NC=>
RPMI 8226MWjGeY5kfGmxbjDBd5NigQ>?NITZc2szOCCwTR?=M4GzdlghcA>?NFv6VVRKdmS3Y3XzJGRPSSC|eX70bIV{cXN?NW[zco46OTl2M{[wOVA>
BaF/3MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX2xNFAhdk1?MVO0PEBpMlSyTWM2OD14LkKgcm0>NYXXfZhHOjB|MEW2PVI>
BaF/3-p210MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV2xNFAhdk1?M4i3R|Q5KGh?Mn3WTWM2OD12Lkegcm0>MVyyNFMxPTZ7Mh?=
TCC-SMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHrHW|AyODBibl2=NXvsVYUzPDhiaB?=M4Lt[GlEPTB;Mj64JI5ONH\6W2kzODNyNU[5Ni=>
BaF/3M1\L[2Z2dmO2aX;uJGF{e2G7NIPkRmo3KG6PM1TxUFQ5KGh?M3;ncGlv\HWlZYOgZUBoemWjdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=>NFzNN3czODNyNU[5Ni=>
BaF/3-p210NUjPcnBmTnWwY4Tpc44hSXO|YYm=M2rYeVYhdk1?MYK0PEBpMnzLTY5lfWOnczDhJJNtcWeqdDDHNUBk\WyuLXP5Z4xmKGG{cnXzeC=>NUHGN2R4OjB|MEW2PVI>
BaF/3-p210M{XXVWZ2dmO2aX;uJGF{e2G7NYfaOYZsPiCwTR?=MmL0NlQhcA>?MonwVoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJIFv\CC2aHWgZYN1cX[rdImgc4YhWmJ?M3[3VFIxOzB3Nkmy
RajiMWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILMTHkyKM7:TR?=MYOyOEBpNV3tZ3ZSWmWmdXPld{Bk\WyuII\pZYJqdGm2edMgNFnodHYzOTF5MEm4PC=>
LCL-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHzETIUyKM7:TR?=NXHaOXZPOjRiaB?=NFP1[nJT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=MXKyNVE4ODl6OB?=
LCL-2MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfZUpMyKM7:TR?=MUCyOEBpM3nicHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?=NV;MepJKOjFzN{C5PFg>
BJABMmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[1NUDPxE1?NWTyXWVQOjRiaB?=NH3z[HNT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=MV6yNVE4ODl6OB?=
SNT-13M2\RXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzLeYEyKM7:TR?=MUeyOEBpNXrnNYtSWmWmdXPld{Bk\WyuII\pZYJqdGm2edMgMkDZNlEyPzB7OEi=
SNT-16MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml7BNUDPxE1?NE\0[YIzPCCqNImzb2VT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC=M2i4[|IyOTdyOUi4
JurkatNF;HfXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHRNUDPxE1?NFrTUXYzPCCqNUPOTllnWmWmdXPld{Bk\WyuII\pZYJqdGm2edMgMknmNlEyPzB7OEi=
KAI-3NYjVU2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnv1NUDPxE1?NIn5OGwzPCCqMoH1VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLiNUXuVmdwOjFzN{C5PFg>
SNK-6NVn6dpBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY[xJO69VQ>?M3ru[VI1KGh?MXvS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?NILPVZozOTF5MEm4PC=>
KHYG-1NUf5NmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;OZ|Eh|ryPM3WyO|I1KGh?MVLS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MonYNlEyPzB7OEi=
SNT-16NHv1PXBCeG:ydH;zbZMhSXO|YYm=NEPxeoQyKM7:TR?=M3e1VFYhcA>?MXnJcoR2[2W|IHPlcIwh[XCxcITvd4l{M{PkUFIyOTdyOUi4
JurkatMXTBdI9xfG:|aYOgRZN{[Xl?NV3p[m1[OSEQvF2=MlP3OkBpNEj3eWVKdmS3Y3XzJINmdGxiYYDvdJRwe2m|NVvocGg5OjFzN{C5PFg>
KAI-3NVnWXmRqSXCxcITvd4l{KEG|c3H5MVuxJO69VQ>?Ml7rOkBpM3nVTGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN?MVOyNVE4ODl6OB?=
KHYG-1NYTRTGl3SXCxcITvd4l{KEG|c3H5M4fkO|Eh|ryPM2D5ZlYhcA>?NUPZZWxNUW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=MoT4NlEyPzB7OEi=
SNT-13NXyyPIlDSW62aY\pdoFtKEG|c3H5NYfrNpQ3OSEQvF2=NVj4UWh2OjRiaB?=M4HxT2lv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>?MnTUNlEyPzB7OEi=
SNT-16MnjiRY51cX[rcnHsJGF{e2G7NWHZdIlyOSEQvF2=MX2yOEBpMW\JcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>MYSyNVE4ODl6OB?=
KAI-3MlfGRY51cX[rcnHsJGF{e2G7MYixJO69VQ>?NXTWVnB2OjRiaB?=MXrJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY>MX:yNVE4ODl6OB?=
SNK-6M3TxOWFvfGm4aYLhcEBCe3OjeR?=MYOxJO69VQ>?MnHUNlQhcA>?NE\wbppKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ?M{G3SFIyOTdyOUi4
RAW 264.7MoOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo[zNVAxKG6PNXz1PXEzPDhiaB?=MYDS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB?MXmyNlQzPzF3NB?=
A375M3jRNGFxd3C2b4Ppd{BCe3OjeR?=NX\vPJZiOTBibl2=MYOyOEBpMWHJcoR2[2W|IHPlcIwh[XCxcITvd4l{MVOyN|A4QTB6Mx?=
BLMNEDi[5ZCeG:ydH;zbZMhSXO|YYm=NHvDOYQyOCCwTR?=MX:yOEBpMmXuTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?MkOxNlMxPzlyOEO=
A375Ml;pRZV1d3CqYXf5JGF{e2G7NEfaTVcyOCCwTR?=MX[xNkBpNYLWPGJCUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM>M3LtSFI{ODd7MEiz
BLMM4PZbWF2fG:yaHHnfUBCe3OjeR?=NEHYU5IyOCCwTR?=MV2xNkBpM33WOGlv\HWlZYOg[o9zdWG2aX;uJI9nKGG3dH;wbIFod3OxbXXzMoLLNlMxPzlyOEO=
H1299NEW1dIhCeG:ydH;zbZMhSXO|YYm=NGe4Zmg5OCCwTR?=MoLhNlQhcA>?M1XzVGROW09?M2fUSXNmdnOrdHn6[ZMhVlOFTFOgZ4VtdHNidH:gUXNENWSncnn2[YQhcUN7LXnu[JVk\WRiYYDvdJRwe2m|MmfBNlU{OjN4OUO=
Hut-78MVzGeY5kfGmxbjDBd5NigQ>?MYWxNFAhdk1?M3\Ve|I1KGh?M1TFSWROW09?M3;VUGRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTBiZYjwdoV{e2mxbh?=NWP3Zo5NOjV4OEGzN|U>
H9NFzYfZFHfW6ldHnvckBCe3OjeR?=NE\HWJYyODBibl2=NHrLc3EzPCCqMlO1SG1UVw>?NX;BSY5{TG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;uM4KxPFI2PjhzM{O1
HHNXTLb2hJTnWwY4Tpc44hSXO|YYm=NYDMeI9vOTByIH7NMnLMNlQhcA>?M4LaNWROW09?M1;HbIRwf26{ZXf1cIF1\XNiVFfGMe6zOSCjbnSgTWwuOTJiZYjwdoV{e2mxbh?=MV6yOVY5OTN|NR?=
Hut-78MUnNbYdz[XSrb36gRZN{[Xl?MoHiNVAxKG6PMYWyOEBpMWTEUXNQNFTGfFdT\WS3Y3XzJINmdGxibXnndoF1cW:wIHL5JFgx6oDVOUClMnf3NlU3QDF|M{W=
HHM1XxZW1q\3KjdHnvckBCe3OjeR?=NWm0NoR{OTByIH7NNETITnYzPCCqNXnMNXFwTE2VTx?=MljTVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlzJR?=NXrFdXJ2OjV4OEGzN|U>
U937MXjGeY5kfGmxbjDBd5NigQ>?MmHSNVAxKG6PMUm2JIg>NF71[IdKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W|MWSyOVc6OTR5Nx?=
human PBMCM{PYemZ2dmO2aX;uJGF{e2G7NES3b4MyODBibl2=NFvTc24zPCCqM4XJOGlv\HWlZYOgTWwuQCC{ZXzlZZNmMof1NlU4QTF2N{e=
ES6NES4ZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DtUGlEPTB;MD6wNFIyKG6PM33UZ3NCVkeHUh?=
SK-UT-1M3G0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXOTWM2OD1yLkG2N{BvVQ>?M2LEXnNCVkeHUh?=
SH-4Ml;1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGW1[VhKSzVyPUCuNVc{KG6PNFnYbXVUSU6JRWK=
TE-9NVTBNJdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mly5TWM2OD1yLkG4NkBvVQ>?NH\iSpdUSU6JRWK=
A253MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTHTWM2OD1yLkKwPEBvVQ>?M4P4OXNCVkeHUh?=
no-10M1r1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTBwMkGgcm0>NIHERm5USU6JRWK=
MMAC-SFM1y0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1nCOGlEPTB;MD6yNVYhdk1?NHzpNWZUSU6JRWK=
A101DMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTBwMkK1JI5ONHX3cpVUSU6JRWK=
NTERA-S-cl-D1MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoW3TWM2OD1yLkK0N{BvVQ>?M{TG[XNCVkeHUh?=
8-MG-BANXWxWZp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGL3PHJKSzVyPUCuNlUhdk1?M1XqN3NCVkeHUh?=
KNS-42MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTBwMkW4JI5ONVXBR5NZW0GQR1XS
LXF-289M{nH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PHUGlEPTB;MD6yOlkhdk1?M2\kWHNCVkeHUh?=
OVCAR-4MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXKTWM2OD1yLkK4PUBvVQ>?NInJOnZUSU6JRWK=
LOUCYMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPTbFZKSzVyPUCuNlk{KG6PNEDoPVlUSU6JRWK=
BB65-RCCMUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDOTWM2OD1yLkOwOEBvVQ>?NHTsW2hUSU6JRWK=
D-542MGMkDPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXP2RVBjUUN3ME2wMlMzQSCwTR?=M1jO[HNCVkeHUh?=
ONS-76NV3rUZRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfUS41KSzVyPUCuN|Mhdk1?Mn3RV2FPT0WU
BB30-HNCM13FRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIrNV|FKSzVyPUCuN|M2KG6PNETaUoxUSU6JRWK=
KS-1MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jMO2lEPTB;MD6zOEBvVQ>?MofuV2FPT0WU
A388NFHwWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHDTWM2OD1yLkO1OkBvVQ>?MYDTRW5ITVJ?
ES8MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPwVlhKSzVyPUCuOEBvVQ>?NU\xSlY5W0GQR1XS
MZ2-MELM1\3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXT3XmdDUUN3ME2wMlQxPyCwTR?=MXjTRW5ITVJ?
HCC2998M1XXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDRVXFKSzVyPUCuOFEzKG6PM4rSfnNCVkeHUh?=
D-247MGNEH0OmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHpTWM2OD1yLkSxN{BvVQ>?MnzmV2FPT0WU
ACNMoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjITWM2OD1yLkSxO{BvVQ>?NELrR5NUSU6JRWK=
LB2518-MELNYDhNo04T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkK4TWM2OD1yLkSyOUBvVQ>?Mne3V2FPT0WU
ES1MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nBW2lEPTB;MD60N{BvVQ>?NVnXPZpsW0GQR1XS
HCE-TNWHxUldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGf1fHpKSzVyPUCuOFM6KG6PMXPTRW5ITVJ?
OS-RC-2M1H6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTBwNESgcm0>NGDUbJVUSU6JRWK=
MFH-inoNXnGO|N1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jHVGlEPTB;MD60OFMhdk1?MV7TRW5ITVJ?
OCUB-MMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTBwNES3JI5OMWjTRW5ITVJ?
CP66-MELNF\iOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTBwNEezJI5OMmG4V2FPT0WU
LB771-HNCMoXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwNEe0JI5OM1KyOXNCVkeHUh?=
DSH1NWf2fm0yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPqb3NKSzVyPUCuOFghdk1?M1vM[3NCVkeHUh?=
HUTU-80MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHuTWM2OD1yLkWzN{BvVQ>?M{Pj[3NCVkeHUh?=
CESSMojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwNUO4JI5ONGPXc2RUSU6JRWK=
NCI-H747M{DPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXNWZpKSzVyPUCuOVM6KG6PMYPTRW5ITVJ?
HT-144M{C4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXtTWM2OD1yLkW3OkBvVQ>?M4LWN3NCVkeHUh?=
COLO-829MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTiXlBRUUN3ME2wMlYyPCCwTR?=NHXm[FRUSU6JRWK=
A4-FukNYTEcI4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\5TWM2OD1yLk[yN{BvVQ>?NWjoeVFtW0GQR1XS
GI-ME-NM3racmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3BTWM2OD1yLk[zOEBvVQ>?MmXqV2FPT0WU
LB831-BLCNWnncmxQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fIdmlEPTB;MD62OFEhdk1?MnvRV2FPT0WU
HOP-62MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvHN|dKSzVyPUCuOlQ4KG6PM1zNTHNCVkeHUh?=
BB49-HNCNYS3SGhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\Q[m8xUUN3ME2wMlY2OiCwTR?=M1P0b3NCVkeHUh?=
D-336MGNVnIfVZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTBwNkW3JI5OMX\TRW5ITVJ?
TK10NGPlfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTBwNke5JI5ONXj6c49tW0GQR1XS
Ramos-2G6-4C10MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFO5XFVKSzVyPUCuOlk{KG6PMV;TRW5ITVJ?
LB373-MEL-DMoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2HmTWlEPTB;MD63JI5OM{jNN3NCVkeHUh?=
SF126NEGzcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MknMTWM2OD1yLkewNUBvVQ>?MnTYV2FPT0WU
UACC-257M{TFOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4LSOGlEPTB;MD63NUBvVQ>?NF3yR|FUSU6JRWK=
KINGS-1NVzGXHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jUbWlEPTB;MD63NlIhdk1?MXXTRW5ITVJ?
LS-513MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGfoPG5KSzVyPUCuO|M6KG6PM3K5NHNCVkeHUh?=
GI-1MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofjTWM2OD1yLke2OEBvVQ>?MWPTRW5ITVJ?
ES7MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTBwN{[2JI5OM2L6dnNCVkeHUh?=
LB2241-RCCMoezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4rMN2lEPTB;MD64NFQhdk1?NITpSXhUSU6JRWK=
D-263MGNXK1TXVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jtXmlEPTB;MD64NFchdk1?MUTTRW5ITVJ?
SW684MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HKZmlEPTB;MD64NlEhdk1?MX;TRW5ITVJ?
ML-2M161dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHuyUohKSzVyPUCuPFIyKG6PMmj3V2FPT0WU
SK-LMS-1M2rRXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIPOc3RKSzVyPUCuPFU1KG6PM{DuVnNCVkeHUh?=
TE-5NH7KU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml71TWM2OD1yLki2OUBvVQ>?NXHa[mRpW0GQR1XS
QIMR-WILM2rEfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwOEi5JI5OMlrJV2FPT0WU
NCI-H1355NVPR[XhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvjZmhKSzVyPUCuPFk2KG6PNVrNT412W0GQR1XS
SNB75NYLKc5Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PCdWlEPTB;MD65NVIhdk1?MlfjV2FPT0WU
RXF393NFXxcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTBwOUG0JI5ONH;0RlVUSU6JRWK=
IST-MEL1NHrxbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTYN4hjUUN3ME2wMlkyPyCwTR?=MoLJV2FPT0WU
SF268MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYTyXpJ3UUN3ME2wMlkzOyCwTR?=MlHRV2FPT0WU
KALS-1MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVfFV243UUN3ME2wMlkzPSCwTR?=NVnLOGNwW0GQR1XS
HC-1NIHVU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2LYW2lEPTB;MD65O|Uhdk1?M4LJ[XNCVkeHUh?=
SW872M3nqTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NULlVpoyUUN3ME2wMlk6PiCwTR?=NGDMPYZUSU6JRWK=
PSN1M1;POGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rPU2lEPTB;MT6wNUBvVQ>?NXSze3JZW0GQR1XS
TE-1NFu1VJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrEVJBKSzVyPUGuNFMhdk1?M{PrdnNCVkeHUh?=
TE-10NXHiPIVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGrVfIZKSzVyPUGuNFMhdk1?MmnDV2FPT0WU
RKONHv4N5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTFwME[gcm0>Mm\4V2FPT0WU
LC-2-adNXPrfItrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;2N4NKSzVyPUGuNFghdk1?M3;2c3NCVkeHUh?=
SK-MM-2MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTkTWM2OD1zLkC5JI5OMXvTRW5ITVJ?
VA-ES-BJMlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXO0enR3UUN3ME2xMlA6KG6PNYPEeXpmW0GQR1XS
MZ7-melMmHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2m5T2lEPTB;MT6wPUBvVQ>?MYLTRW5ITVJ?
D-392MGM{fwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnrUTWM2OD1zLkGgcm0>M3jUdnNCVkeHUh?=
CCRF-CEMNIDFOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLUWJBKSzVyPUGuNVMhdk1?NYS1[2pXW0GQR1XS
EM-2NX3ndo93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXXJR|UxRTFwMU[gcm0>MnPlV2FPT0WU
HAL-01M4iwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\0do5bUUN3ME2xMlE5KG6PNWXxfHlqW0GQR1XS
TE-8MkO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jX[GlEPTB;MT6xPUBvVQ>?NYHqdWFnW0GQR1XS
NCI-H1882NXP6UmZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DKVWlEPTB;MT6yJI5ONInUWJNUSU6JRWK=
DaudiMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILUWo5KSzVyPUGuNlIhdk1?MV;TRW5ITVJ?
BL-41Ml\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrOXnVKSzVyPUGuNlUhdk1?MkjpV2FPT0WU
SRMV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M363[WlEPTB;MT6yOUBvVQ>?NEX6blJUSU6JRWK=
KM12NEHxUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXhZ25KSzVyPUGuNlchdk1?MUPTRW5ITVJ?
K5MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPmV45KSzVyPUGuNlghdk1?NIT1S|RUSU6JRWK=
A3-KAWM33ndGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPMTWM2OD1zLkK4JI5OM4\jOnNCVkeHUh?=
CMKMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHTDcmZKSzVyPUGuNlkhdk1?MVPTRW5ITVJ?
Calu-6NFTJdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWDaeW1wUUN3ME2xMlI6KG6PM3LmVXNCVkeHUh?=
IST-SL2MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRTFwM{Ggcm0>MULTRW5ITVJ?
OPM-2NY\FRopxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV7JR|UxRTFwM{Ogcm0>M3XSVHNCVkeHUh?=
DU-4475MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF3yOVhKSzVyPUGuN|Yhdk1?NWPxbo9XW0GQR1XS
ECC12Ml[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\ZcplQUUN3ME2xMlM4KG6PMoG4V2FPT0WU
L-540NWjOV3h{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLoTWM2OD1zLkO3JI5ONYi0NIxGW0GQR1XS
CAS-1NEfFbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fmcWlEPTB;MT6zO{BvVQ>?M2HIfnNCVkeHUh?=
PF-382M2W5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwNEegcm0>NYPhU3NSW0GQR1XS
LS-411NNGnhNI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYXJR|UxRTFwNUOgcm0>NVLDfZF5W0GQR1XS
NCI-H69Ml73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUXJ[nBSUUN3ME2xMlU1KG6PMmHOV2FPT0WU
NB12M37UNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrXd4NKSzVyPUGuOVYhdk1?MXnTRW5ITVJ?
HELMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljFTWM2OD1zLk[xJI5OM2HSOXNCVkeHUh?=
GCIYMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTFwNkKgcm0>M1jPXXNCVkeHUh?=
EHEBNEfaR|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvsTWM2OD1zLk[3JI5ONHjUVGxUSU6JRWK=
TGBC1TKBNV;Q[Fg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPMfWU6UUN3ME2xMlcyKG6PMlfGV2FPT0WU
KURAMOCHIM3jESmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{D6TmlEPTB;MT63NkBvVQ>?MlrGV2FPT0WU
U-266NF7SW2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTFwN{[gcm0>MYXTRW5ITVJ?
LC4-1M3\uW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnyTWM2OD1zLke5JI5OMUjTRW5ITVJ?
NCI-H2126MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1T2V2lEPTB;MT64JI5ONFXt[pFUSU6JRWK=
NCI-H1092MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF;UPXdKSzVyPUGuPEBvVQ>?NWTXfVRDW0GQR1XS
GB-1NYXZOXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlzsTWM2OD1zLkixJI5OMUPTRW5ITVJ?
MV-4-11M{jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{XkZmlEPTB;MT64NkBvVQ>?M3zwcXNCVkeHUh?=
BeckerM4TFUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTFwOEOgcm0>MVPTRW5ITVJ?
MPP-89M1;4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXrJR|UxRTFwOEmgcm0>NXj5WlZYW0GQR1XS
BE-13M1fnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTFwOUOgcm0>M{TmUHNCVkeHUh?=
697NVLGfoFyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mne0TWM2OD1zLkm5JI5ONUDybZFOW0GQR1XS
NKM-1NFPhWJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M164WGlEPTB;MjDuUS=>M1uxdHNCVkeHUh?=
NB13MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVniVVlVUUN3ME2yJI5ONEm2dphUSU6JRWK=
LS-123Mk\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTJwMEKgcm0>MlXEV2FPT0WU
NB17MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTJwMESgcm0>M3\afnNCVkeHUh?=
LAN-6M2nPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTJwMEWgcm0>M3;6e3NCVkeHUh?=
EW-24NYf0NpFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYroXIJZUUN3ME2yMlA5KG6PNEfzUGxUSU6JRWK=
NOS-1NUj6VVBJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\LTWM2OD1{LkGxJI5OM1HueXNCVkeHUh?=
BL-70NVTofoduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL2PHRKSzVyPUKuNVIhdk1?M{LNNXNCVkeHUh?=
GT3TKBM322S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvSSVNHUUN3ME2yMlEzKG6PMl3MV2FPT0WU
HHNXvw[ZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYnES5A{UUN3ME2yMlE{KG6PNIPHSY1USU6JRWK=
KE-37NGjzeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvNNo1KSzVyPUKuNVMhdk1?NV\nTGNbW0GQR1XS
MOLT-4NXriXoc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkOwTWM2OD1{LkGzJI5ONWnnb497W0GQR1XS
EKVXMomzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXac2w6UUN3ME2yMlE1KG6PMkDmV2FPT0WU
KGNM2S1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfhN3V1UUN3ME2yMlE2KG6PNYfUcmp5W0GQR1XS
ES4NXruXJRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTJwMU[gcm0>M1\1dXNCVkeHUh?=
SJSA-1M2jMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonMTWM2OD1{LkKxJI5ONYf6WWQ{W0GQR1XS
KMOE-2M4TLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHzvc4ZKSzVyPUKuNlMhdk1?NEjBXZlUSU6JRWK=
NB5NELxdY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUfNcWozUUN3ME2yMlI4KG6PMkjrV2FPT0WU
BC-1M{XITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVnJR|UxRTJwM{Ggcm0>NHiyZoRUSU6JRWK=
NB10Ml;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;1TWM2OD1{LkOyJI5OMnTsV2FPT0WU
RPMI-8226M4\jdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnXNlVKSzVyPUKuN|Uhdk1?MX\TRW5ITVJ?
SCC-3NVTybZVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXz1fHBmUUN3ME2yMlM4KG6PNEPRTYdUSU6JRWK=
ARH-77MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPEWnVnUUN3ME2yMlM5KG6PMUnTRW5ITVJ?
NCI-H748NVy3eGFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYmyPG42UUN3ME2yMlM6KG6PM1\tUHNCVkeHUh?=
KU812Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1j3c2lEPTB;Mj60NkBvVQ>?NHO4ZoRUSU6JRWK=
NCI-H64Mk\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXLOemxGUUN3ME2yMlQ1KG6PNH30WFBUSU6JRWK=
NB69MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{n4TGlEPTB;Mj60OkBvVQ>?NHLEZWdUSU6JRWK=
KNS-81-FDMmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYTOd|ZZUUN3ME2yMlQ5KG6PM3;rV3NCVkeHUh?=
LB1047-RCCNFHGbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3KcpdKSzVyPUKuOVchdk1?M{P4ZnNCVkeHUh?=
EB-3MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2nHd2lEPTB;Mj62OkBvVQ>?M4Lsd3NCVkeHUh?=
Mo-TNGWwWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLTeXgzUUN3ME2yMlc1KG6PM4qxZ3NCVkeHUh?=
EW-16NIKyWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHmNoJKSzVyPUKuO|Uhdk1?MWrTRW5ITVJ?
CTV-1M4PMfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn7STWM2OD1{Lkigcm0>MXPTRW5ITVJ?
ETK-1Ml61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJwOESgcm0>M174R3NCVkeHUh?=
C2BBe1Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDsTWM2OD1{Lki5JI5ONVjPdXd[W0GQR1XS
MOLT-16M4fJR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX74OpA{UUN3ME2yMlg6KG6PNUT3UYdHW0GQR1XS
SW954NWLnN4xkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NELFSmJKSzVyPUKuPUBvVQ>?NInZSJVUSU6JRWK=
HTMn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\WTWM2OD1|LkCyJI5ONFXJUmlUSU6JRWK=
KARPAS-299NIrsbXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfld45xUUN3ME2zMlA3KG6PNYPwPXVuW0GQR1XS
MONO-MAC-6NYPEZZVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWK4OJZUUUN3ME2zMlEhdk1?NHfOWWpUSU6JRWK=
CGTH-W-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVX6cVhlUUN3ME2zMlEhdk1?MoW1V2FPT0WU
SK-PN-DWNUTFT2hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGXDUZBKSzVyPUOuNVQhdk1?Mnz6V2FPT0WU
CW-2MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTNwMkGgcm0>MkfRV2FPT0WU
SK-N-DZMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\hb4Z6UUN3ME2zMlI3KG6PNWHVWIV6W0GQR1XS
NEC8Mnz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXNTWM2OD1|LkO1JI5ONFLhSFhUSU6JRWK=
LB996-RCCMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;GTWM2OD1|LkSgcm0>NVH6[YdmW0GQR1XS
DBM{[yT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEjjXpVKSzVyPUOuOFEhdk1?NWDRc24{W0GQR1XS
TE-15NYm5PWpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q3N2lEPTB;Mz60N{BvVQ>?NIn3bGRUSU6JRWK=
COR-L88MoXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXnFWYdWUUN3ME2zMlQ4KG6PNWS2XlNEW0GQR1XS
LAMA-84NIi1NlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vHN2lEPTB;Mz60PUBvVQ>?NVLjfWtKW0GQR1XS
MEG-01MnrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3qwcmlEPTB;Mz60PUBvVQ>?MkHxV2FPT0WU
LOXIMVINWSxT3NYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTNwNTDuUS=>MWPTRW5ITVJ?
RPMI-8402NEf3O4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvjV2VKSzVyPUOuOUBvVQ>?M3W4OHNCVkeHUh?=
KARPAS-45Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFjnT4RKSzVyPUOuOVQhdk1?MljUV2FPT0WU
HCC1187NY\qcoZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2HId2lEPTB;Mz61OEBvVQ>?MljhV2FPT0WU
MZ1-PCNYrCdGx2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mm\QTWM2OD1|LkW0JI5ONXviVnF5W0GQR1XS
no-11NHzITpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTNwNUWgcm0>NYfmWJJLW0GQR1XS
EVSA-TNWLjfWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjFeJF2UUN3ME2zMlYhdk1?M{jpbnNCVkeHUh?=
DJM-1Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX6ydJhQUUN3ME2zMlY{KG6PNEP2XlZUSU6JRWK=
COLO-684NHnZUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXnJR|UxRTNwNk[gcm0>NYjVb|RXW0GQR1XS
NMC-G1NWjZWodYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTNwNkigcm0>MXLTRW5ITVJ?
LC-1FMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\Ve4V3UUN3ME2zMlc1KG6PMXfTRW5ITVJ?
RL95-2M1jLSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTCSJhKSzVyPUOuO|khdk1?M4XyZ3NCVkeHUh?=
COLO-320-HSRNXS4fYNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHKdZRFUUN3ME2zMlkzKG6PMoDBV2FPT0WU
RCC10RGBMoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmfaTWM2OD1|LkmzJI5OM4DFVnNCVkeHUh?=
HD-MY-ZMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTNwOUOgcm0>MYTTRW5ITVJ?
NCI-H2141MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoX1TWM2OD12LkC1JI5OMX\TRW5ITVJ?
K-562M{\Memdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnFPHJUUUN3ME20MlEzKG6PNUDkTGgyW0GQR1XS
NCI-H1648M1fjNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUi3NZB{UUN3ME20MlE{KG6PMV\TRW5ITVJ?
OMC-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXrJR|UxRTRwMUigcm0>NFu5codUSU6JRWK=
LB647-SCLCM{L4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHqeFRKSzVyPUSuNlIhdk1?MkS4V2FPT0WU
TE-12NGThOllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MojiTWM2OD12LkK1JI5OMoL0V2FPT0WU
NOMO-1M{L0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{GwfGlEPTB;ND6zN{BvVQ>?MYjTRW5ITVJ?
RajiMWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkCyTWM2OD12LkS2JI5OM2DHdXNCVkeHUh?=
NALM-6NUXpWGZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlXETWM2OD12LkS5JI5OM134RXNCVkeHUh?=
HL-60MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHH0XItKSzVyPUSuOlchdk1?M{\wSXNCVkeHUh?=
IST-SL1M1P3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLyTWM2OD12Lk[4JI5OM37ufHNCVkeHUh?=
MHH-PREB-1NWixdndDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPhPJhiUUN3ME20Mlg3KG6PM1zr[XNCVkeHUh?=
MHH-NB-11M{W0W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEn5fmVKSzVyPUSuPVEhdk1?NXLXU2NOW0GQR1XS
JiyoyeP-2003M3zHV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4K4OGlEPTB;NTDuUS=>Ml\wV2FPT0WU
SBC-1M3rvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXX5U3NuUUN3ME21MlAyKG6PNILscIJUSU6JRWK=
CHP-126MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnvUFBKSzVyPUWuNFYhdk1?MYLTRW5ITVJ?
LU-139Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIDIUpFKSzVyPUWuNVMhdk1?MVTTRW5ITVJ?
NCI-SNU-5NYLzR|JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rTW2lEPTB;NT6xO{BvVQ>?NWfEVmZLW0GQR1XS
SW962NFi5O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUjsTGY2UUN3ME21MlIyKG6PMUfTRW5ITVJ?
EW-1MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoH6TWM2OD13LkOxJI5ONWfmc|RjW0GQR1XS
NCI-H1417MnvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLTWo5KSzVyPUWuOVEhdk1?NYnJOFdbW0GQR1XS
LU-65M3TqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlyzTWM2OD13Lki0JI5OM3jy[HNCVkeHUh?=
D-502MGMnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfiTWM2OD14LkO3JI5OMYfTRW5ITVJ?
BC-3MlPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkTjTWM2OD14Lk[xJI5ONHq4W4pUSU6JRWK=
GDM-1NI\uWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jGcGlEPTB;Nj63O{BvVQ>?MmLGV2FPT0WU
NCI-H2196NHnmRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrtSVNKSzVyPU[uPEBvVQ>?MmXtV2FPT0WU
NB1NUDEV|JIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2q5WGlEPTB;Nj64PEBvVQ>?NXTEeYdjW0GQR1XS
NCI-H345MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWraUI5QUUN3ME23MlIhdk1?NVHrbJNzW0GQR1XS
SU-DHL-1NWfQeFNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{XDcWlEPTB;Nz6yOEBvVQ>?MYjTRW5ITVJ?
JVM-2M2\ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUW4XYFKUUN3ME23MlI5KG6PNVfoVXBYW0GQR1XS
LU-134-AMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTdwM{mgcm0>NHTucGpUSU6JRWK=
NCI-H1694MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrQdo1KSzVyPUeuOVghdk1?NU\vfVNSW0GQR1XS
NCI-SNU-16MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHGNVFKSzVyPUeuOlUhdk1?MWjTRW5ITVJ?
L-363M4Tne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnUe4dKSzVyPUeuO{BvVQ>?MkP0V2FPT0WU
KG-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXUc4FKUUN3ME23Mlk1KG6PNETYdWdUSU6JRWK=
MN-60NWi1TldrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn74TWM2OD16LkG0JI5OM3m4XHNCVkeHUh?=
NB6NVTjNXlOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFHoZnFKSzVyPUiuOFghdk1?MkTrV2FPT0WU
MLMAM4TPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\ucG5KSzVyPUiuPFUhdk1?NFfERYhUSU6JRWK=
ATN-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoXBTWM2OD16Lki5JI5ONGS1XoJUSU6JRWK=
SK-NEP-1MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXtTWM2OD17LkCxJI5ONHiwTXlUSU6JRWK=
DMS-114MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTlwNkKgcm0>M3npfXNCVkeHUh?=
CTB-1NGrF[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV30VFBRUUN3ME25MlY4KG6PM{TI[XNCVkeHUh?=
NCI-H2081NWDNNmhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\aRXhKSzVyPUGwMlA6KG6PMl;EV2FPT0WU
ES5M4S5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzLNGtKSzVyPUGwMlM5KG6PM3rZfHNCVkeHUh?=
HCC1599MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjmTWM2OD1zMT65NUBvVQ>?NEKyPVFUSU6JRWK=
NCI-H23NG\yeZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfGTWM2OD1zMj6xNkBvVQ>?NW\tOGVuW0GQR1XS
NCI-H1581NWPReZhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTF{LkK4JI5ONEDrNZVUSU6JRWK=
JVM-3MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTF{Lkm5JI5ONX60WFhvW0GQR1XS
NCI-SNU-1NFH1fXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTF|LkG5JI5ONXLYNI5KW0GQR1XS
NB7NWXKZYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjGZW5WUUN3ME2xOU46OiCwTR?=MmL6V2FPT0WU
JARNILGPHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TLO2lEPTB;MU[uNVMhdk1?NEfyU45USU6JRWK=
TGWNGj4dmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjYTHlKSzVyPUG2MlQ5KG6PM1LHOnNCVkeHUh?=
U-87-MGNI\5d|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGnzV5ZKSzVyPUG2Mlc3KG6PNYLJV5hmW0GQR1XS
NCI-H1436MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIq5WmpKSzVyPUG3MlAyKG6PNH30WYZUSU6JRWK=
GOTOMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTF5LkC2JI5OM2mzfnNCVkeHUh?=
COLO-800MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHJZWJKSzVyPUG3MlY1KG6PNEjKbGxUSU6JRWK=
MFM-223M1TmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojETWM2OD1zNz65NUBvVQ>?NIjDeYFUSU6JRWK=
EW-18MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NITnXmdKSzVyPUG3Mlk3KG6PMYPTRW5ITVJ?
NB14MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF5Lkm4JI5ONV3xO3BHW0GQR1XS
EB2M1PmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYqzUGtUUUN3ME2xPE4xQCCwTR?=NIq0UGdUSU6JRWK=
EoL-1-NXnv[lNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFf3bIxKSzVyPUG4MlMyKG6PMoLmV2FPT0WU
NCCITNX3qcFEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV3JR|UxRTF6LkO2JI5OMkHyV2FPT0WU
DG-75NWfGUo5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH0SohmUUN3ME2xPE43OSCwTR?=NFv6boFUSU6JRWK=
HCC2218MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjpTWM2OD1zOT61JI5OMl[zV2FPT0WU
TE-6NFv0Z5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LHemlEPTB;MkCuNFghdk1?MofOV2FPT0WU
SF539MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{\KbmlEPTB;MkCuOlchdk1?M{DOOHNCVkeHUh?=
NCI-H446M2qwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{T5RWlEPTB;MkGuNVghdk1?Mlv1V2FPT0WU
IST-MES1NVPlc2RET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nmcWlEPTB;MkKuO|chdk1?M4PPSHNCVkeHUh?=
NCI-H82NF3LWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfTZ|Z3UUN3ME2yN{4xOiCwTR?=NV3XdVV[W0GQR1XS
HCC2157NEHxWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX7JR|UxRTJ|LkGzJI5ONWLFbmNZW0GQR1XS
EW-12M3WyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjz[4E1UUN3ME2yN{4yPyCwTR?=Mn6yV2FPT0WU
SIMAM4Pke2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1XmSGlEPTB;MkOuN|ghdk1?NWPXPJE3W0GQR1XS
DOHH-2M1fNSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2PJT2lEPTB;MkOuOFUhdk1?MV\TRW5ITVJ?
IM-9M4PUcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDvdFNwUUN3ME2yN{42PCCwTR?=MVnTRW5ITVJ?
EC-GI-10NG\hW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTJ2LkKzJI5ONXLNfJdDW0GQR1XS
HDLM-2NIPGcVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETRW|hKSzVyPUK0MlU1KG6PM1;CbnNCVkeHUh?=
LS-1034M2fVRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYD3dHJmUUN3ME2yOU44PSCwTR?=NXX4WHpJW0GQR1XS
REHMmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYLnVpZEUUN3ME2yOk41OSCwTR?=MoLDV2FPT0WU
LU-165NHrnPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\jTWM2OD1{Nj63NkBvVQ>?MYjTRW5ITVJ?
NH-12NGTR[oJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nQOmlEPTB;MkeuOlchdk1?MoLpV2FPT0WU
WSU-NHLNVSycVcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTJ6LkO5JI5OMmTqV2FPT0WU
ECC4MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;lSmlEPTB;MkiuO|khdk1?M1TqNnNCVkeHUh?=
OCI-AML2NV65NGFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\WbmxKSzVyPUK5MlY6KG6PNEHkZo1USU6JRWK=
EW-3NV7HUnpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX74cGlyUUN3ME2zNE42QSCwTR?=NEnQbmxUSU6JRWK=
NCI-H526NWq1doU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDUTWM2OD1|Mj61OEBvVQ>?NXnIOlI1W0GQR1XS
NCI-H719M3nBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlzDTWM2OD1|ND6zNUBvVQ>?M3j5b3NCVkeHUh?=
KARPAS-422MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\QdVBKSzVyPUO1MlA1KG6PMnLjV2FPT0WU
SK-MEL-1M{XTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVPHVpk{UUN3ME2zOU4yPyCwTR?=MnXEV2FPT0WU
ES3MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7MU2xmUUN3ME2zOU4yQSCwTR?=NHfieGtUSU6JRWK=
UACC-812NH3QUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvUXYM5UUN3ME2zOU41PCCwTR?=MoTPV2FPT0WU
C8166M3rEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTN3Lkegcm0>M1HMfHNCVkeHUh?=
MDA-MB-134-VIMoDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1nybGlEPTB;M{WuPFchdk1?MnzSV2FPT0WU
D-283MEDNXTjPYQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGK5OnlKSzVyPUO3Mlc6KG6PNVvGVHFXW0GQR1XS
SHP-77MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUOwUnJOUUN3ME2zPE4xOyCwTR?=MYLTRW5ITVJ?
NCI-H2227MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILE[WdKSzVyPUSwMlQ6KG6PMV7TRW5ITVJ?
SKM-1MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXr2Wm9PUUN3ME20Nk43OyCwTR?=NIjJZZhUSU6JRWK=
L-428NUH5N40zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnHcYlKSzVyPUSzMlg3KG6PNWHHXIVJW0GQR1XS
RPMI-6666M1LXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVzUOVY4UUN3ME20OU45QSCwTR?=M1y3VXNCVkeHUh?=
NCI-H716Mn7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTR6LkixJI5ONEjZNWdUSU6JRWK=
DMS-79MkfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrncHRKSzVyPUWwMlcyKG6PM3TS[3NCVkeHUh?=
RS4-11MlLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDXeIVKSzVyPUWwMlg5KG6PNXLQO2xbW0GQR1XS
NCI-H720NYTuSploT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3rNUmlEPTB;NUGuNVEhdk1?MXHTRW5ITVJ?
MC-CARNIm2RmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTVzLkWyJI5ONF;PW2JUSU6JRWK=
TALL-1NYjDbZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDwZ5M2UUN3ME21N{46OSCwTR?=NF;kdlZUSU6JRWK=
NCI-N87NX3aenpsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILrcG1KSzVyPUW0MlE5KG6PNEG3[llUSU6JRWK=
P30-OHKNX;vZ4ZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3zzc2lEPTB;NUSuOlEhdk1?MWnTRW5ITVJ?
LP-1M4PxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MorpTWM2OD14MT6yPEBvVQ>?M1z3[nNCVkeHUh?=
YTNF3LOpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnHJTWM2OD14MT64JI5OMlTVV2FPT0WU
MRK-nu-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3pNYNKSzVyPU[xMlgzKG6PMUfTRW5ITVJ?
BT-474M{TJVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4XHNGlEPTB;NkWgcm0>M4LFO3NCVkeHUh?=
NCI-H322MM2nhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYf1[HN[UUN3ME22Ok4yOSCwTR?=NV\hVZJLW0GQR1XS
NCI-H128MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoqwTWM2OD15ND63O{BvVQ>?NETCWYZUSU6JRWK=
KMS-12-PEMmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4jaVGlEPTB;N{[uNlQhdk1?MV3TRW5ITVJ?
KP-N-YSMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTd4Lke0JI5ONFfPWZZUSU6JRWK=
ALL-PONYHCSHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrWTWM2OD15Nz62OkBvVQ>?M3LxUXNCVkeHUh?=
EW-13MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXpTWM2OD15Nz63OkBvVQ>?NEexVVZUSU6JRWK=
EW-11MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTd6LkWyJI5ONIPLW3JUSU6JRWK=
SK-N-FINXPPeVd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHTlPW5KSzVyPUiwMlIhdk1?M3[0dXNCVkeHUh?=
CAL-148NFO3eI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn25TWM2OD16MT64OEBvVQ>?NWj0c2Z1W0GQR1XS
RLNVrOblZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTh4LkC5JI5ONELlUG9USU6JRWK=
AM-38MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmTtTWM2OD16OD6wPEBvVQ>?MUPTRW5ITVJ?
RH-1MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIXTRW9KSzVyPUm5Mlg2KG6PM1izTXNCVkeHUh?=
NCI-H1770NGL4THhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTFyMj60PUBvVQ>?MVjTRW5ITVJ?
SIG-M5MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjLTWM2OD1zMEWuNFYhdk1?NETMeY1USU6JRWK=
GR-STNGnSXGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XkRWlEPTB;MUGzMlM1KG6PNF3Wc29USU6JRWK=
ST486MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\PXFRKUUN3ME2xNVQvODZibl2=MXvTRW5ITVJ?
NCI-H1650M2rqU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnadnY2UUN3ME2xNVUvOjlibl2=NVTuV4VnW0GQR1XS
MHH-CALL-2NWewXZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEX2SHVKSzVyPUGxOU44KG6PM4HuWXNCVkeHUh?=
BV-173NV75RZRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknVTWM2OD1zMkKuO|Ehdk1?MWTTRW5ITVJ?
MC116M2G5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfVc4RKSzVyPUG0PE45PSCwTR?=NXTqWYZkW0GQR1XS
NCI-H524MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXzJR|UxRTF3OT6xJI5OMnzOV2FPT0WU
SCLC-21HNYDDTZl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTF3OT60NUBvVQ>?NGXvbYlUSU6JRWK=
NCI-H1304MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXvZcGxSUUN3ME2xOlkvOjFibl2=NEmyO21USU6JRWK=
NCI-H510ANX3LVGZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\3O2pKSzVyPUG4OU4{PyCwTR?=NXnyS4R2W0GQR1XS
NCI-H209NIPyUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mme2TWM2OD1zOU[uOVIhdk1?MnjTV2FPT0WU
KM-H2MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHUfmJKSzVyPUG5O{4xPSCwTR?=M4PYfXNCVkeHUh?=
NCI-H1395MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{[3b2lEPTB;MkGwMlE{KG6PMUPTRW5ITVJ?
NCI-H1155NVPQOlR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;ncWlEPTB;MkOwMlMzKG6PM3jDOHNCVkeHUh?=
COR-L279Mkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXjJR|UxRTJ3Mj6xO{BvVQ>?MofiV2FPT0WU
NCI-H1299M1\sV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rpfmlEPTB;Mk[xMlcyKG6PNXnyWJFpW0GQR1XS
EW-22MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTJ4Mz63OUBvVQ>?M2rlenNCVkeHUh?=
SK-MEL-2M4DsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITCfmlKSzVyPUK4NU46KG6PNVPu[nJIW0GQR1XS
KASUMI-1MkTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jWV2lEPTB;MkizMlA2KG6PNF\uSYVUSU6JRWK=
NCI-H187NUTQ[YJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTJ6Nz6wPEBvVQ>?NIHMcVVUSU6JRWK=
NCI-H2171Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHfFV5dKSzVyPUK4PE46OiCwTR?=NIHOXY1USU6JRWK=
LNCaP-Clone-FGCNFTNdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWHJR|UxRTJ7NT6yOkBvVQ>?MWLTRW5ITVJ?
NCI-H1522M2HVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3K2[2lEPTB;M{C3MlA2KG6PNI\xNHRUSU6JRWK=
SCHMkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPnTWM2OD1|MkKuNlIhdk1?Mnn4V2FPT0WU
THP-1NGjp[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHHOJB[UUN3ME2zNlIvPiCwTR?=NET2VoRUSU6JRWK=
SNU-C1Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXBTWM2OD1|NkKuNFkhdk1?NUDvPGR2W0GQR1XS
CA46NXPONW9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zYZWlEPTB;M{ezMlY{KG6PM1W5OnNCVkeHUh?=
NCI-H1963NXjZWXVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWmxRVE{UUN3ME2zPFYvOTlibl2=NHS1c|RUSU6JRWK=
DELM2CyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUPQfnFwUUN3ME2zPVEvOjdibl2=MnXaV2FPT0WU
TURMoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIq2eZZKSzVyPUO5Ok43OSCwTR?=MkX2V2FPT0WU
NCI-H226M1XwRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUX1bXd3UUN3ME20NFMvOjNibl2=MmjIV2FPT0WU
COLO-668Mlm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXracFc6UUN3ME20NFMvPTdibl2=NEnY[2tUSU6JRWK=
CPC-NMULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPFN3NKSzVyPUSwN{44PyCwTR?=M1TGUnNCVkeHUh?=
NCI-H889NXfxUXk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH2yb3pKSzVyPUS2NU46OiCwTR?=MoPZV2FPT0WU
J-RT3-T3-5NEW5VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvtOm96UUN3ME21N|IvPTdibl2=M1zPenNCVkeHUh?=
MSTO-211HM3\hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\KTZgxUUN3ME21O|QvOjZibl2=MU\TRW5ITVJ?
SCC-15MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTZ4Nz60O{BvVQ>?MWfTRW5ITVJ?
SUP-T1NHPl[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFflWVhKSzVyPU[4Ok4xPCCwTR?=MWrTRW5ITVJ?
DMS-153MmDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlHMTWM2OD15NE[uPFMhdk1?Mn3TV2FPT0WU
MS-1MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIPYeYFKSzVyPUe1PU41OiCwTR?=M1fq[nNCVkeHUh?=
TC-YIKMmTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTd6MT6wNUBvVQ>?M36wT3NCVkeHUh?=
RPMI-8866NUKzTGl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmnWTWM2OD1zMEC2MlI5KM7:TR?=NXS3TYZYW0GQR1XS
KY821NH3zcHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmnxTWM2OD1zMEO2MlA1KM7:TR?=M2PSO3NCVkeHUh?=
P31-FUJMkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTFzMUKuO|Uh|ryPNH7wS5FUSU6JRWK=
COLO-824M1;0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M37zW2lEPTB;MUK2NU44QCEQvF2=M17hcHNCVkeHUh?=
U-698-MNGnaNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUHXPVB5UUN3ME2yNlYzNjF3IN88US=>NV;1XZFyW0GQR1XS
TE-441-TNHPy[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3zzRmlEPTB;MkWyNU44KM7:TR?=NYnMVml5W0GQR1XS
IMR-5M3qxNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUizc3k3UUN3ME2zOFA6NjZ{IN88US=>MnLyV2FPT0WU
NCI-H1838NF[4[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rEVmlEPTB;NEG4Ok4{OiEQvF2=NEHBOWFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]
Features

Protocol(Only for Reference)

Kinase Assay:

[4]

Kinetic Methods In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.

Cell Assay:

[5]

Cell lines Human multiple myeloma cells line U266
Concentrations ~10 μM
Incubation Time 2 days
Method

The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.

Animal Study:

[3]

Animal Models Human plasmacytoma xenografts RPMI 8226
Formulation Saline
Dosages 1 mg/kg
Administration i.v. twice weekly for 4 weeks, then once weekly

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Adams J, et al. Cancer Res, 1999, 59(11), 2615-2622.

[2] Boccadoro M, et al. Cancer Cell Int, 2005, 5(1):18.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02605356 Not yet recruiting Multiple Myeloma Bayer March 2016 Phase 1|Phase 2
NCT02518750 Recruiting Acute Lymphoblastic Leukemia|Lymphoma, Non-Hodgkins|Leukemia, T-Cell|Leukemia, B-Cell St. Jude Childrens Research Hospital|Novartis Pharmaceuti  ...more St. Jude Childrens Research Hospital|Novartis Pharmaceuticals December 2015 Phase 2
NCT02613598 Not yet recruiting Hodgkins Lymphoma|Lymphoma, Non-Hodgkin University of Michigan Cancer Center December 2015 Phase 1
NCT02441686 Recruiting Multiple Myeloma Dana-Farber Cancer Institute|Millennium Pharmaceuticals,  ...more Dana-Farber Cancer Institute|Millennium Pharmaceuticals, Inc.|Celgene Corporation December 2015 Phase 2
NCT02563340 Not yet recruiting Kidney Transplantation First Affiliated Hospital, Sun Yat-Sen University|Second  ...more First Affiliated Hospital, Sun Yat-Sen University|Second Affiliated Hospital of Guangzhou Medical University November 2015 Phase 1|Phase 2

view more

Chemical Information

Download Bortezomib (PS-341) SDF
Molecular Weight (MW) 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms LDP-341, MLM341
Solubility (25°C) * In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% methylcellulose/0.2% Tween 80 5 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name B-​[(1R)​-​3-​methyl-​1-​[[(2S)​-​1-​oxo-​3-​phenyl-​2-​[(2-​pyrazinylcarbonyl)​amino]​propyl]​amino]​butyl]​-boronic acid

Customer Product Validation (20)


Click to enlarge
Rating
Source Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck
Method Western blots
Cell Lines Primary myoblasts
Concentrations 10, 50 uM
Incubation Time 24 h
Results To demonstrate the biological functionality of the salvaged missense mutated dysferlin protein, we performed membrane resealing experiments on primary myoblasts derived from percutaneous muscle biopsies taken from patient 2. Bortezomib treatment of primary myoblasts increased dysferlin expression in a dose-dependent manner, and bortezomib-treated myoblasts regained their capability to reseal laser-induced plasma membrane injuries.

Click to enlarge
Rating
Source J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck
Method Fluorescence
Cell Lines Primary myoblasts
Concentrations 2 mg/kg
Incubation Time 2 weeks
Results To examine this further, it determined whether inhibition of the proteasome with bortezomib blocked proplatelet formation in murine megakaryocytes. Similar responses were observed in human megakaryocytes, and removal of bortezomib from the incubation media restored proplatelet formation.

Click to enlarge
Rating
Source J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines Mouse primary osteoblasts
Concentrations 25 nM
Incubation Time 2 h
Results In support of this idea, the PTH-induced decrease of HDAC4 accumulation in osteoblasts was prevented by the addition of an inhibitor of proteasomal degradation, bortezomib.

Click to enlarge
Rating
Source Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck
Method H&E staining, Western blots, TUNEL assays
Cell Lines Foxp3flox/yxPBCre4+ mice
Concentrations 1 mg/kg
Incubation Time 60 weeks
Results Reduced cell proliferation was also observed in prostate epithelial cells of bortezomib-treated mice by Ki67 staining analysis (A). Furthermore, lack of nuclear p65 was observed in the bortezomib-treated prostate at 12 hours after LPS injection (B). To verify the impact of bortezomib treatment on NF-kB activation, we observed the expression of NF-kB targets in the mouse prostate. In contrast to the prostate-specific expression in untreated Foxp3cKO mice, the expression levels of Bcl2l1 and Traf1/2 were significantly downregulated in the prostates of treated mice (C). Importantly, the percentage of apoptotic prostate epithelial cells increased after bortezomib treatment (D).

Click to enlarge
Rating
Source Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence microscopy
Cell Lines HeLa cells
Concentrations 100 nM
Incubation Time 45 min
Results Bortezomib and NH4Cl also increased the adjacency of DRIPs to SGs.

Click to enlarge
Rating
Source Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines wild-type oocytes, Fmn2-/-oocytes
Concentrations 0.1 μM
Incubation Time 90 min
Results Endogenous Fmn2, localized in the cortex of prophase I oocytes, disappeared at NEBD, reappeared later and was enriched in the cortex opposite the spindle. Fmn2 -/-oocytes lacked cortical Fmn2 staining, suggesting that the staining is specific. Cortical localization was maintained at NEBD in wild-type oocytes treated with the proteasome inhibitor, Bortezomib, indicating that Fmn2 is degraded at NEBD.

Click to enlarge
Rating
Source Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence Analysis
Cell Lines RS4;11cells
Concentrations 2.5 nM
Incubation Time 22 h
Results In RS4;11 samples combined treatment induces Ser536 p-NF-κB nuclear translocation (see white arrows).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method Luciferase assay
Cell Lines LNCaP-AI cells, LNCaP cells
Concentrations 20 μM
Incubation Time 24 h
Results EGF significantly stimulates the promoter activity of sPLA2-IIa gene in both LNCaP and LNCaP-AI cells (shown in LNCaP-AI cells), whereas Bortezomib and other inhibitors tested downregulated the promoter activity both at the basal level (shown in LNCaP cells) and in response to EGF stimulation (shown in LNCaP-AI cells).

Click to enlarge
Rating
Source Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck
Method ELISA
Cell Lines LNCaP-AI cells
Concentrations 20 μM
Incubation Time 24 h
Results Bortezomib, Lapatinib, and LY294002 significantly inhibited sPLA2-IIa secretion, whereas Erlotinib, Gefitinib and CI-1033 had a moderate effect in LNCaP-AI cells.

Click to enlarge
Rating
Source J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck
Method Real Time PCR
Cell Lines HepAD38 cells
Concentrations 2-50 nM
Incubation Time 18 h
Results An inhibitory effect of proteasome inhibition by bortezomib on HBV replication can be observed in cell culture.Therefore, proteasome activation seems to be a valuable strategy of the infected cells to reduce the stress resulting from misfolded proteins.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 0.1-10 μM
Incubation Time 1/7 h
Results Proteasome inhibitors which have different inhibition mechanisms, such as bortezomib and lactacystin, had a strong effect on virus replication in parallel with an increase in p53 accumulation.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines MA104 cells
Concentrations 10 μM
Incubation Time 5-10 h
Results Further kinetic experiments were performed to better define the time window within the viral replication cycle in which proteasome activity was required. For this, cells were infected for 1 h and treated with MG132 or bortezomib for 4h at different times postinfection (Fig. A). As shown in Fig. B, a more clear arrest on viral protein accumulation was observed when bortezomib or MG132 was added at relatively earlier time points. Indeed, when inhibitors were added at 5 h p.i. or later, the effect was much reduced, suggesting that once the infection was well established with a robust accumulation of viroplasms, the requirement for proteasome activity was less significant.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Immunofluorescence
Cell Lines NSP5-EGFP cells
Concentrations 10 μM
Incubation Time 2-8 h
Results Both MG132 and bortezomib induced a significant arrest on the formation of viroplasms, which appeared in reduced number and with smaller size with respect to those in control cells, particularly when added at time points between 1 h and 5 h p.i.

Click to enlarge
Rating
Source J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck
Method Quantification of viroplasms
Cell Lines NSP5-EGFP cells, MA104 cells
Concentrations 10 μM
Incubation Time 4 h
Results The number of viroplasms per cell in cells treated for 4 h with MG132 or bortezomib was almost the same as that found in cells fixed at the beginning of each treatment, strongly suggesting that inhibition of proteasome activity affected the assembly of new viroplasms and their growth.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Proteasome activity assay, Standard plaque assay
Cell Lines A549 cells
Concentrations 10-100 nM
Incubation Time 1 h
Results As expected bortezomib treatment resulted in a block of viral replication of the avian influenzavirus strain A/FPV/Bratislava/79 (H7N7; FPV) in a concentration-dependent manner. While concentrations of 10 nM had no antiviral effect, 50 nM led to a significant titer reduction of up to 3 orders of magnitude (Fig.A). The highest concentration used (100 nM) led to a titer reduction of up to 4 orders of magnitude.These results were also confirmed in a virus growth kinetics study in infected cells that received a single dose of 50nM bortezomib. Virus titers were reduced at every time point analyzed (Fig.C).Since bortezomib is a proteasome inhibitor, we investigated whether the antiviral concentrations of bortezomib may have an inhibitory effect on the 26S proteasome in A549 cells. A concentration-dependent inhibition of the proteasome was observed in FPV-infected A549 cells at 24 h p.i. (Fig. B).

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Standard plaque assay, Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1-10 h
Results A strong antiviral activity of bortezomib was observed upon addition of the compound up to 2 h p.i. At time points of 4 h p.i. and later, a dramatic decrease in the antiviral efficacy was observed. This indicates that the event in the viral life cycle that is affected by bortezomib occurs within the first 4 h. Since this correlates with the strong onset of viral gene and protein expression, we analyzed whether viral protein accumu-lation is affected by bortezomib. Indeed, we observed a strong reduction in viral matrix protein (M1) and PB1 polymerase synthesis in FPV- and PR8-infected cells at 5 h and 8 h p.i.

Click to enlarge
Rating
Source J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck
Method Western blot
Cell Lines A549 cells
Concentrations 50 nM
Incubation Time 1/6/24 h
Results After a 6-h treatment with 50 nM bortezomib, activation of JNK was detected as evidenced by phosphorylation of the kinase at Thr183 and Tyr185 (lane 4). This was even enhanced upon a 24-h treatment (lane 6). Downstream substrates of JNK are the AP-1 transcription factors c-Jun and ATF-2, which are activated by JNK-mediated phosphorylation at Ser63 and Thr71, respectively. Consistent with JNK activation, we also found c-Jun and ATF-2 were phosphorylated and activated( lane 6), leading to the conclusion that, besides NF-κB, the JNK/c-Jun/ATF-2 pathway is also activated in A549 upon bortezomib treatment.

Click to enlarge
Rating
Source PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck
Method Western blotting
Cell Lines HEK293 cells
Concentrations 50 μM
Incubation Time 4 h
Results Upon proteasome inhibition by Bortezomib an increased amount of around 5-6 fold of biotinylated molecules was detected, both in the absence and presence of US2 and US11.

Click to enlarge
Rating
Source 2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck
Method Western Blotting
Cell Lines KKU-M213 cells
Concentrations 0/20/40 nM
Incubation Time 0-12 h
Results We checked the effects of BTZ on the NF-κB pathway in KKU-M213 (Fig. a, b). BTZ induced IκB phosphorylation in dose- and time-dependent manners (Fig. a). Interestingly, reduced IκB was observed over time until it was barely detectable 12 h after treatment; as a result, nuclear NF-κB (p65) was markedly increased (Fig. b).

Click to enlarge
Rating
Source Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck
Method PB assay
Cell Lines S2-013
Concentrations
Incubation Time 24 h
Results It is noticed more deleterious effects by free bortezomib than by BTZ CS/GA nanoparticles.

Product Use Citation (142)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Proteasome Products

  • VR23

    VR23 is a potent proteasome inhibitor with IC50 of 1 nM, 50-100 nM, and 3 μM for trypsin-like proteasomes, chymotrypsin-like proteasomes, and caspase-like proteasomes, respectively.

  • Calpeptin

    Calpeptin is a potent, cell-permeable calpain inhibitor with ID50 of 52 nM, 34 nM, 138 nM, and 40 nM for Calpain I (porcine erythrocytes), Calpain II (porcine kidney), Papainb, and Calpain I (human platelets), respectively.

  • Marimastat(BB-2516)

    Marimastat (BB-2516) is a broad spectrum matrix metalloprotease (MMP) inhibitor for MMP-9, MMP-1, MMP-2, MMP-14 and MMP-7 with IC50 of 3 nM, 5 nM, 6 nM, 9 nM and 13 nM, respectively. Phase 3.

  • MG-132

    MG-132 is an inhibitor of proteasome with IC50 of 100 nM in a cell-free assay, and also inhibits calpain with IC50 of 1.2 μM.

  • Carfilzomib (PR-171)

    Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities.

  • Ixazomib (MLN2238)

    MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31 and 3500 nM. Phase 3.

    Features:A first-in-class proteasome inhibitor that has improved pharmacokinetics (PK), pharmacodynamics(PD), and antitumor activity in preclinical studies.

  • ONX-0914 (PR-957)

    ONX-0914 (PR-957) is a potent and selective immunoproteasome inhibitor with minimal cross-reactivity for the constitutive proteasome in a cell-free assay.

    Features:The first highly selective, small molecule inhibitor of the immunoproteasome. Potential use in cancer and autoimmune diseases (e.g. rheumatoid arthritis, inflammatory bowel disease, and lupus).

  • MLN9708

    MLN9708 immediately hydrolyzed to MLN2238, the biologically active form, on exposure to aqueous solutions or plasma. MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/Ki of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Phase 3.

    Features:The 1st oral proteasome inhibitor in early stage clinical trials for Multiple Myeloma.

  • Celastrol

    Celastrol is a potent proteasome inhibitor for the chymotrypsin-like activity of a purified 20S proteasome with IC50 of 2.5 μM.

    Features:A potent antioxidant and anti-inflammatory drug.

  • Oprozomib (ONX 0912)

    Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2.

Recently Viewed Items

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) ic50 | Bortezomib (PS-341) price | Bortezomib (PS-341) cost | Bortezomib (PS-341) solubility dmso | Bortezomib (PS-341) purchase | Bortezomib (PS-341) manufacturer | Bortezomib (PS-341) research buy | Bortezomib (PS-341) order | Bortezomib (PS-341) mouse | Bortezomib (PS-341) chemical structure | Bortezomib (PS-341) mw | Bortezomib (PS-341) molecular weight | Bortezomib (PS-341) datasheet | Bortezomib (PS-341) supplier | Bortezomib (PS-341) in vitro | Bortezomib (PS-341) cell line | Bortezomib (PS-341) concentration | Bortezomib (PS-341) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us